Close Menu

NEW YORK – A team led by researchers at mass spectrometry firm Protypia and drugmaker Eli Lilly has demonstrated the ability of targeted mass spec to quantify immune checkpoint inhibitor targets in patient tissue.

Detailed in a study published this week in Scientific Reports, the work showed that mass spectrometry can provide a more accurate assessment of the expression of checkpoint proteins like PD-L1 than conventional clinical approaches like immunohistochemistry.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.